May 27, 2016
Using a Cellecta-made shRNA library, groups from the European Institute of Oncology and MD Anderson Cancer Center published the first in vivo pooled RNAi screen in patient-derived tumor xenograft PDX mouse models. The study published in June Cancer Discovery screened 236 epigenetic genes targeted with a pooled shRNA...
Read More January 17, 2014
Researchers at the German Cancer Research Center (DKFZ) and the MD Anderson Cancer Center used Cellecta's shRNA DECIPHER Libraries for an in vivo genetic screen that identified SALL1 as a breast cancer tumor suppressor that plays a role in E-cadherin regulation (Article)E-cadherin (CDH1) has been shown to have a...
Read More June 10, 2013
Researchers at the German Cancer Research Center (DKFZ) used Cellecta's shRNA DECIPHER libraries to identify genes that sensitize pancreatic cells to gemcitabine.Pancreatic cancer has only a 6% 5-year survival rate. Gemcitabine is the standard treatment in conjunction with surgery to remove cancerous...
Read More March 20, 2012
Our group recently ran across an article describing an independent RNAi screen with a non-Cellecta pooled shRNA expression library that piqued our interest. In the October 2011 online Genome Biology Journal, Sims, et al. comprehensively described how to run a rigorous genome-wide pooled RNA interference screen...
Read More February 03, 2012
A couple of months ago at the CHI Discovery on Target Conference, Hakim Djaballah, Director of the HTS Core Facility at the Memorial Sloan Kettering Cancer Center, gave a unique and insightful presentation highlighting the challenges RNAi screening to identify lethal loss of function interaction in oncogenic...
Read More October 14, 2011
We recently received a phase II of our SBIR grant Exploiting Synthetic Lethality of Hematopoietic Lineage Cells to Develop Novel Targets from the NIH. Rather than trying to identify potential drug targets in oncogenic hematopoietic cells, much of the effort for this project focuses on trying to develop a...
Read More August 31, 2011
Therapeutic approaches using multiple drug combinations have become a standard treatment model for many types of cancer. Due to the tremendous genetic complexity and adaptive nature of most human malignancies, the use of multiple drugs acting on different targets increases the efficacy and helps thwart the...
Read More August 03, 2011
The last blog entry discussed how hairpin structural features affect representation and effectiveness of shRNA sequences in pooled libraries. However, it is clear that the nucleotide sequence is possibly the major factor that determines the efficiency at which a particular siRNA or shRNA knocks down a...
Read More May 13, 2011
Inducible expression is often desirable for functional genetic testing to establish clear cause and effect for a specific phenotype. A particular phenotype can be demonstrably linked to expression of a specific cDNA by showing it disappears when transcription is suppressed. Although less direct, similar logic...
Read More April 03, 2011
Researchers are often interested in using a pooled shRNA library for genome-wide RNAi screening to cast a very “wide and unbiased net to identify any and all genes functionally involved in some pathway”. Although it is not difficult to make an shRNA library targeting all human or mouse genes, it is practically very...
Read More March 30, 2011
Take the opportunity at SBS 2011 to learn about Cellecta's cancer drug target discovery services. Come visit us at booth #522, and be sure not to miss our oral presentation and tutorial on Wednesday, March 30:HT RNAi Screening of Anti-Cancer Targets With Pooled shRNA LibrariesSpeaker: Alex Chenchik, Ph.D.Alex...
Read More February 25, 2011
The addition of the 3rd DECIPHER Human shRNA Expression Library Module to the DECIPHER pooled shRNA library collection adds approximately 5,000 new cell surface, extracellular, and DNA binding target genes...
Read More February 18, 2011
Since we provide both constitutive and tetracycline-inducible versions of both U6 and H1 shRNA promoters,...
Read More February 15, 2011
Cellecta's recent agreement with the Roswell Park Cancer Institute (RPCI) provides support to laboratories in their institution doing genome-wide RNAi...
Read More